Human cytomegalovirus controls a new autophagy-dependent cellular antiviral defense mechanism

被引:114
作者
Chaumorcel, Magali [1 ]
Souquere, Sylvie
Pierron, Gerard [2 ]
Codogno, Patrice [1 ,2 ]
Esclatine, Audrey [1 ]
机构
[1] Univ Paris Sud 11, Fac Pharm, INSERM, UMR756, F-92296 Chatenay Malabry, France
[2] Inst Andre Lwoff, CNRS, FRE 2937, Lab Replicat IADN & Ultrastruct Noyau, Villejuif, France
关键词
cytomegalovirus; cellular defense; xenophagy; mTOR; LC3;
D O I
10.4161/auto.5184
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that remains the major infectious cause of birth defects, as well as being an important opportunistic pathogen. Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved process responsible for the degradation of cytoplasmic macromolecules, and the elimination of damaged organelles via a lysosomal pathway. This process is also triggered in organisms by stressful conditions and by certain diseases. Previous observations have suggested that autophagy (also known as xenophagy in this case) may contribute to innate immunity against viral infections. Recent studies on HSV-1, another herpesvirus, have shown that HSV-1 is able to avoid this cellular defense by means of a viral protein, ICP34.5, which antagonizes the host autophagy response. However, it was not known whether HCMV was also able to counteract autophagy. Here, we show that HCMV infection drastically inhibits autophagosome formation in primary human fibroblasts. Autophagy was assessed by GFP-LC3 redistribution, LC3-II and p62 accumulation and electron microscopy. Inhibition of autophagy occurred early in the infection by a mechanism involving viral protein(s). Indeed, only infected cells expressing viral proteins displayed a striking decrease of autophagy; whereas bystander, non-infected cells displayed a level of autophagy similar to that of control cells. HCMV activated the mTOR signaling pathway, and rendered infected cells resistant to rapamycin-induced autophagy. Moreover, infected cells also became resistant to the stimulation of autophagy by lithium chloride, an mTOR-independent inducer of autophagy. These findings suggest that HCMV has developed efficient strategies for blocking the induction of autophagy during infection.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 47 条
[1]  
[Anonymous], 2001, FIELDS VIROLOGY
[2]   Thinking globally and acting locally with TOR [J].
Arsham, Andrew M. ;
Neufeld, Thomas P. .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (06) :589-597
[3]   p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death [J].
Bjorkoy, G ;
Lamark, T ;
Brech, A ;
Outzen, H ;
Perander, M ;
Overvatn, A ;
Stenmark, H ;
Johansen, T .
JOURNAL OF CELL BIOLOGY, 2005, 171 (04) :603-614
[4]   PHOSPHORYLATION OF RIBOSOMAL-PROTEIN S6 IS INHIBITORY FOR AUTOPHAGY IN ISOLATED RAT HEPATOCYTES [J].
BLOMMAART, EFC ;
LUIKEN, JJFP ;
BLOMMAART, PJE ;
VANWOERKOM, GM ;
MEIJER, AJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (05) :2320-2326
[5]   Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection [J].
Cassady, KA .
JOURNAL OF VIROLOGY, 2005, 79 (14) :8707-8715
[6]   Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1 [J].
Child, SJ ;
Hakki, M ;
De Niro, KL ;
Geballe, AP .
JOURNAL OF VIROLOGY, 2004, 78 (01) :197-205
[7]   Autophagy and signaling: their role in cell survival and cell death [J].
Codogno, P ;
Meijer, AJ .
CELL DEATH AND DIFFERENTIATION, 2005, 12 (Suppl 2) :1509-1518
[8]   Maturation of autophagic vacuoles in mammalian cells [J].
Eskelinen, Eeva-Liisa .
AUTOPHAGY, 2005, 1 (01) :1-10
[9]  
ESPERT L, 2007, J MOL MED
[10]   Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4 [J].
Espert, Lucile ;
Denizot, Melanie ;
Grimaldi, Marina ;
Robert-Hebmann, Veronique ;
Gay, Bernard ;
Varbanov, Mihayl ;
Codogno, Patrice ;
Biard-Piechaczyk, Martine .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (08) :2161-2172